In the studies with pembrolizumab, the positivity of tissues for PD-L1 is defined, using the 22C3 antibody (Merck, Co., Inc., Kenilworth, NJ, USA), as at least ≥1% positive tumor cells. Here, CD274 is linked to neoplasm.